文献速递心脑血管急症消化、代谢与肾脏急症

高消化道出血风险的非瓣膜性房颤患者口服抗凝药比较

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
PubMed 文献 · JAMA Netw Open · 2021-08-02
一句话结论高消化道出血风险的非瓣膜性房颤患者中,所有NOAC较华法林降低卒中/系统性栓塞风险,但大出血风险因NOAC种类而异。

所有NOAC较华法林降低卒中/系统性栓塞风险;阿哌沙班和达比加群降低大出血风险,利伐沙班增加大出血风险。结果提示在该高危人群中NOAC种类选择需权衡卒中预防与大出血风险。

要点

  • 高消化道出血风险NVAF患者中,阿哌沙班较华法林降低卒中/系统性栓塞风险(HR 0.60,95%CI 0.52-0.68)。
  • 达比加群较华法林降低卒中/系统性栓塞风险(HR 0.75,95%CI 0.64-0.88),利伐沙班亦降低(HR 0.79,95%CI 0.73-0.86)。
  • 阿哌沙班(HR 0.59,95%CI 0.56-0.63)和达比加群(HR 0.78,95%CI 0.70-0.86)较华法林降低大出血风险。
  • 利伐沙班较华法林增加大出血风险(HR 1.11,95%CI 1.05-1.16),在该人群中需谨慎选择。
  • 该研究为回顾性队列,结果需前瞻性验证,不能直接作为床旁决策阈值。

适用人群与场景

  • 非瓣膜性房颤患者,年龄≥75岁,或III-V期慢性肾脏病,或HAS-BLED评分≥3,或使用糖皮质激素/抗血小板药/NSAIDs,或存在消化道疾病。
  • 数据来源为Centers for Medicare & Medicaid Services及4个商业保险数据库,2012年1月1日至2015年9月30日。

诊断标准与关键阈值

  • 高消化道出血风险因素包括:年龄≥75岁;III-V期慢性肾脏病;HAS-BLED评分≥3;使用糖皮质激素、抗血小板药或NSAIDs;消化道疾病。
  • HAS-BLED评分≥3定义为高出血风险(原文中74.7%患者HAS-BLED≥3)。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。
  • 研究暴露为新处方阿哌沙班、达比加群、利伐沙班或华法林(2013年1月1日至2015年9月30日识别期)。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 主要终点卒中/系统性栓塞:阿哌沙班vs华法林HR 0.60(95%CI 0.52-0.68);达比加群vs华法林HR 0.75(95%CI 0.64-0.88);利伐沙班vs华法林HR 0.79(95%CI 0.73-0.86)。
  • 大出血:阿哌沙班vs华法林HR 0.59(95%CI 0.56-0.63);达比加群vs华法林HR 0.78(95%CI 0.70-0.86);利伐沙班vs华法林HR 1.11(95%CI 1.05-1.16)。
  • 采用倾向性评分匹配创建6个队列,Cox模型估计风险比。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:回顾性设计,数据来自保险数据库,可能存在混杂和未测量变量;结果需前瞻性验证。

对床旁实践的改变

  • 在高消化道出血风险的非瓣膜性房颤患者中,选择NOAC时需考虑不同NOAC的大出血风险差异:阿哌沙班和达比加群较华法林降低大出血风险,利伐沙班增加大出血风险。
  • 该研究结果可辅助个体化抗凝决策,但不能替代前瞻性随机试验证据。

指南或共识出处

  • JAMA Netw Open

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Many patients with nonvalvular atrial fibrillation (NVAF) are at a high risk of gastrointestinal (GI) bleeding due to conditions including older age; stage III to V chronic kidney disease (CKD); HAS-BLED (hypertension, kidney or liver disease, stroke history, prior bleeding, unstable international normalized ratio, age >65, drug or alcohol use) score of 3 or greater; corticosteroid, antiplatelet or nonsteroidal anti-inflammatory drug (NSAID) use; or GI conditions.

OBJECTIVE: To compare the risk of stroke and/or systemic embolism (SE) and major bleeding (MB) among patients with NVAF and high risk of GI bleeding who received non-vitamin K antagonist oral anticoagulants (NOACs) vs those who received warfarin.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients with NVAF who were 75 years and older; had stage III to V CKD; had an HAS-BLED score of 3 or greater; used corticosteroids, antiplatelets, or NSAIDs; or had GI conditions. Data were collected from the Centers for Medicare & Medicaid Services and 4 commercial insurance databases between January 1, 2012, and September 30, 2015. Data analysis was conducted from January 2012 to September 2015.

EXPOSURES: New prescription for apixaban, dabigatran, rivaroxaban, or warfarin between January 1, 2013, and September 30, 2015 (identification period).

MAIN OUTCOMES AND MEASURES: Six propensity score-matched cohorts were created to compare between study drugs. For the primary objective, Cox models were used to estimate stroke and/or SE and MB hazard ratios (HRs).

RESULTS: A total of 381 054 patients (187 489 [49.2%] women) with NVAF and at least 1 high-risk GI bleeding factor were identified (HAS-BLED score ≥3: 284 527 [74.7%]; aged ≥75 years: 252 835 [66.4%]; corticosteroid, antiplatelet, or NSAID therapy: 107 675 [28.3%]; prior GI bleeding conditions: 74 818 [19.6%]; and stage III-V CKD: 56 892 [14.9%]). All NOACs were associated with a lower risk of stroke and/or SE vs warfarin (apixaban: HR, 0.60; 95% CI, 0.52-0.68; dabigatran: HR, 0.75; 95% CI, 0.64-0.88; rivaroxaban: HR, 0.79; 95% CI, 0.73-0.86). Compared with warfarin, apixaban and dabigatran were associated with a lower risk of MB (apixaban: HR, 0.59; 95% CI, 0.56-0.63; dabigatran: HR, 0.78; 95% CI, 0.70-0.86), while rivaroxaban was associated with a higher risk (HR, 1.11; 95% CI, 1.05-1.16).

CONCLUSIONS AND RELEVANCE: In this study of patients with NVAF and high risk of GI bleed, NOACs were associated with lower rates of stroke and/or SE, but NOACs had varying risks of MB compared with warfarin. These results may help inform treatment options in this patient population.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Lip GYH, Keshishian AV, Zhang Y, et al. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. JAMA Netw Open. 2021. PMID: 34398204. doi:10.1001/jamanetworkopen.2021.20064

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。